Table 2: Clinical trials assessing PD-1 or PD-L1 immune checkpoint inhibitors in combination with other therapy in NSCLC.
| Clinical Trials | Lines of Treatment | Phase | Sample Size | ORR (%) | PFS (Months) | OS |
| Checkmate 012: Nivolumab + PT-DC | 1 | One | 56 | 46% | 6 months | Median 19 months |
| 2-year: 25% | ||||||
| Keynote 021: | 1 | Two | ||||
| 18 months OS: | ||||||
| Pembrolizumab + Carbo + Pem | 57 | 19 | 70% | |||
| Carbo + Pem | 32 | 8.9 | 56% | |||
| Atezolizumab + PT-DC | 1 | One | 37 | Not Reported | Not Reported | |
| Atezolizumab + Carbo + Paclitaxel | 8 | 60 | ||||
| Atezolizumab + Carbo + Pemetrexed | 14 | 75 | ||||
| Atezolizumab + Carbo + Nab-paclitaxel | 15 | 62 | ||||
| Checkmate 012: Nivo + Ipilimumab | 1 | One | 77 | |||
| 24 weeks (%) | ||||||
| Nivo 3 mg/kg + Ipilimumab 1 mg/kg Q12w | 47 | 68 | Not Reported | |||
| Nivo 3 mg/kg + Ipilimumab 1 mg/kg Q6w | 38 | 47 | Not Reported |
ORR: Overall Response Rate; PFS: Progression Free Survival; OS: Overall Survival; AEs: Adverse Effects; PT-DC: Platinum-based doublet chemotherapy; Nivo: Nivolumab; Gem: Gemcitabine; Cis: Cisplatin; Pem: Pemetrexed; Carbo: Carboplatin; SqNSCLC: Squamous non-small cell lung cancer.